Modality
Gene Therapy
MOA
PARPi
Target
PSMA
Pathway
T-cell
NSCLC
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
~Dec 2021
→ ~Mar 2023
Phase 3
Jun 2023
→ Oct 2028
Phase 3Current
NCT06870343
960 pts·NSCLC
2023-06→2028-10·Completed
960 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-252.6y awayPh3 Readout· NSCLC
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Complet…
Catalysts
Ph3 Readout
2028-10-25 · 2.6y away
NSCLC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06870343 | Phase 3 | NSCLC | Completed | 960 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |